184 related articles for article (PubMed ID: 28336937)
1. Results of the randomized phase IIB ARCTIC trial of low-dose rituximab in previously untreated CLL.
Howard DR; Munir T; McParland L; Rawstron AC; Milligan D; Schuh A; Hockaday A; Allsup DJ; Marshall S; Duncombe AS; O'Dwyer JL; Smith AF; Longo R; Varghese A; Hillmen P
Leukemia; 2017 Nov; 31(11):2416-2425. PubMed ID: 28336937
[TBL] [Abstract][Full Text] [Related]
2. Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial.
Howard DR; Munir T; McParland L; Rawstron AC; Chalmers A; Gregory WM; O'Dwyer JL; Smith A; Longo R; Varghese A; Smith A; Hillmen P
Health Technol Assess; 2017 May; 21(28):1-374. PubMed ID: 28628003
[TBL] [Abstract][Full Text] [Related]
3. Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL.
Munir T; Howard DR; McParland L; Pocock C; Rawstron AC; Hockaday A; Varghese A; Hamblin M; Bloor A; Pettitt A; Fegan C; Blundell J; Gribben JG; Phillips D; Hillmen P
Leukemia; 2017 Oct; 31(10):2085-2093. PubMed ID: 28216660
[TBL] [Abstract][Full Text] [Related]
4. Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial.
Collett L; Howard DR; Munir T; McParland L; Oughton JB; Rawstron AC; Hockaday A; Dimbleby C; Phillips D; McMahon K; Hulme C; Allsup D; Bloor A; Hillmen P
Trials; 2017 Aug; 18(1):387. PubMed ID: 28830517
[TBL] [Abstract][Full Text] [Related]
5. Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia.
Short NJ; Keating MJ; Wierda WG; Faderl S; Ferrajoli A; Estrov Z; Smith SC; O'Brien SM
Cancer; 2015 Nov; 121(21):3869-76. PubMed ID: 26218678
[TBL] [Abstract][Full Text] [Related]
6. A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia.
Hillmen P; Cohen DR; Cocks K; Pettitt A; Sayala HA; Rawstron AC; Kennedy DB; Fegan C; Milligan DW; Radford J; Mercieca J; Dearden C; Ezekwisili R; Smith AF; Brown J; Booth GA; Varghese AM; Pocock C;
Br J Haematol; 2011 Mar; 152(5):570-8. PubMed ID: 21231927
[TBL] [Abstract][Full Text] [Related]
7. Low-dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD-FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experience.
Herishanu Y; Tadmor T; Braester A; Bairey O; Aviv A; Rahimi-Levene N; Fineman R; Levi I; Yuklea M; Ruchlemer R; Shvidel L; Polliack A
Hematol Oncol; 2019 Apr; 37(2):185-192. PubMed ID: 30756414
[TBL] [Abstract][Full Text] [Related]
8. Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in non-del(17p) CLL.
Appleby N; O'Brien D; Quinn FM; Smyth L; Kelly J; Parker I; Scott K; Cahill MR; Crotty G; Enright H; Hennessy B; Hodgson A; Leahy M; O'Leary H; O'Dwyer M; Hayat A; Vandenberghe EA
Leuk Lymphoma; 2018 Jun; 59(6):1338-1347. PubMed ID: 28925785
[TBL] [Abstract][Full Text] [Related]
9. Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia.
Mato AR; Foon KA; Feldman T; Schuster SJ; Svoboda J; Chow KF; Valentinetti M; Mrkulic M; Azzollini K; Gadaleta G; Bhattacharyya PK; Zenreich J; Pascual LN; Yannotti K; Kdiry S; Howlett C; Strelec L; Porter D; Bejot C; Goy A
Am J Hematol; 2015 Jun; 90(6):487-92. PubMed ID: 25691474
[TBL] [Abstract][Full Text] [Related]
10. [Clinical efficacy and safety of chemoimmunotherapy with rituximab,fludarabine and cyclophosphamide for chronic lymphocytic leukemia].
Li F; Yi SH; Yu Z; Xing LJ; Xu Y; Qi JY; Zhao YZ; Li ZJ; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2013 May; 34(5):383-8. PubMed ID: 23688746
[TBL] [Abstract][Full Text] [Related]
11. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study.
Dartigeas C; Van Den Neste E; Léger J; Maisonneuve H; Berthou C; Dilhuydy MS; De Guibert S; Leprêtre S; Béné MC; Nguyen-Khac F; Letestu R; Cymbalista F; Rodon P; Aurran-Schleinitz T; Vilque JP; Tournilhac O; Mahé B; Laribi K; Michallet AS; Delmer A; Feugier P; Lévy V; Delépine R; Colombat P; Leblond V; ;
Lancet Haematol; 2018 Feb; 5(2):e82-e94. PubMed ID: 29275118
[TBL] [Abstract][Full Text] [Related]
12. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia.
Bosch F; Abrisqueta P; Villamor N; Terol MJ; González-Barca E; Ferra C; González Diaz M; Abella E; Delgado J; Carbonell F; García Marco JA; Escoda L; Ferrer S; Monzó E; González Y; Estany C; Jarque I; Salamero O; Muntañola A; Montserrat E
J Clin Oncol; 2009 Sep; 27(27):4578-84. PubMed ID: 19704063
[TBL] [Abstract][Full Text] [Related]
13. [Rituximab infusion-related toxicity in patients with chronic lymphocytic leukemia].
Šimkovič M; Vodárek P; Motyčková M; Žák P; Smolej L
Vnitr Lek; 2015; 61(7-8):626-32. PubMed ID: 26375688
[TBL] [Abstract][Full Text] [Related]
14. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication.
Bosch F; Ferrer A; Villamor N; González M; Briones J; González-Barca E; Abella E; Gardella S; Escoda L; Pérez-Ceballos E; Asensi A; Sayas MJ; Font L; Altés A; Muntañola A; Bertazzoni P; Rozman M; Aymerich M; Giné E; Montserrat E
Clin Cancer Res; 2008 Jan; 14(1):155-61. PubMed ID: 18172266
[TBL] [Abstract][Full Text] [Related]
15. High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance.
García-Marco JA; Jiménez JL; Recasens V; Zarzoso MF; González-Barca E; De Marcos NS; Ramírez MJ; Parraga FJP; Yañez L; De La Serna Torroba J; Malo MDG; Ariznavarreta GD; Persona EP; Guinaldo MAR; De Paz Arias R; Llanos EB; Jarque I; Valle MDCF; Tatay AC; De Oteyza JP; Martin EMD; Fernández IP; Martinez RM; Costa MAA; Champ D; Suarez JG; Díaz MG; Ferrer S; Carbonell F; García-Vela JA;
Haematologica; 2019 Nov; 104(11):2249-2257. PubMed ID: 30890600
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial.
Assouline S; Buccheri V; Delmer A; Gaidano G; Trneny M; Berthillon N; Brewster M; Catalani O; Li S; McIntyre C; Sayyed P; Badoux X
Lancet Haematol; 2016 Mar; 3(3):e128-38. PubMed ID: 26947201
[TBL] [Abstract][Full Text] [Related]
17. Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments.
Laurenti L; Innocenti I; Autore F; Vannata B; Efremov DG; Ciolli S; Del Poeta G; Mauro FR; Cortelezzi A; Borza PA; Ghio F; Mondello P; Murru R; Gozzetti A; Cariccio MR; Piccirillo N; Boncompagni R; Cantonetti M; Principe MI; Reda G; Bongarzoni V; Cervetti G; Pitini V; Foà R; Sica S; D'Arena G
Leuk Res; 2015 Oct; 39(10):1066-70. PubMed ID: 26307523
[TBL] [Abstract][Full Text] [Related]
18. Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib.
Wang XV; Hanson CA; Tschumper RC; Lesnick CE; Braggio E; Paietta EM; O'Brien S; Barrientos JC; Leis JF; Zhang CC; Coutre SE; Barr PM; Cashen AF; Mato AR; Singh AK; Mullane MP; Erba H; Stone R; Litzow MR; Tallman MS; Shanafelt TD; Kay NE
Blood; 2021 Dec; 138(26):2810-2827. PubMed ID: 34407545
[TBL] [Abstract][Full Text] [Related]
19. Impact of novel agents on patient-relevant outcomes in patients with previously untreated chronic lymphocytic leukemia who are not eligible for fludarabine-based therapy.
Singh M; Mealing S; Baculea S; Cote S; Whelan J
J Med Econ; 2017 Oct; 20(10):1066-1073. PubMed ID: 28720054
[TBL] [Abstract][Full Text] [Related]
20. Prognostic role of CD4 T-cell depletion after frontline fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukaemia.
Gauthier M; Durrieu F; Martin E; Peres M; Vergez F; Filleron T; Obéric L; Bijou F; Quillet Mary A; Ysebaert L
BMC Cancer; 2019 Aug; 19(1):809. PubMed ID: 31412798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
